acquired
Stage
3
Investors
About
Ablynx is a biopharmaceutical company specializing in the discovery and development of nanobodies, a class of proprietary therapeutic proteins designed to treat serious human diseases including inflammation, haematology, immuno-oncology, oncology, and respiratory diseases.
Explore Ablynx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.